| Literature DB >> 28811532 |
Irina M Larina1, Andrew J Percy2, Juncong Yang2, Christoph H Borchers2,3,4,5, Andrei M Nosovsky1, Anatoli I Grigoriev1, Evgeny N Nikolaev6,7,8.
Abstract
The effects of spaceflight on human physiology is an increasingly studied field, yet the molecular mechanisms driving physiological changes remain unknown. With that in mind, this study was performed to obtain a deeper understanding of changes to the human proteome during space travel, by quantitating a panel of 125 proteins in the blood plasma of 18 Russian cosmonauts who had conducted long-duration missions to the International Space Station. The panel of labeled prototypic tryptic peptides from these proteins covered a concentration range of more than 5 orders of magnitude in human plasma. Quantitation was achieved by a well-established and highly-regarded targeted mass spectrometry approach involving multiple reaction monitoring in conjunction with stable isotope-labeled standards. Linear discriminant function analysis of the quantitative results revealed three distinct groups of proteins: 1) proteins with post-flight protein concentrations remaining stable, 2) proteins whose concentrations recovered slowly, or 3) proteins whose concentrations recovered rapidly to their pre-flight levels. Using a systems biology approach, nearly all of the reacting proteins could be linked to pathways that regulate the activities of proteases, natural immunity, lipid metabolism, coagulation cascades, or extracellular matrix metabolism.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28811532 PMCID: PMC5557884 DOI: 10.1038/s41598-017-08432-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
P-values for proteins which show significant differences at the p < 0.05 level with the LSD Test.
| Protein | Time-points Compared | ||
|---|---|---|---|
| L-30 vs R + 1 | L-30 vs R + 7 | R + 1 vs R + 7 | |
| 78 kDa glucose-regulated protein | 0.016231-Dec | ns | ns |
| Alpha-2-antiplasmin | 0.032056-Dec | ns | ns |
| Apolipoprotein A-I | 0.005682-Dec | 0.029907-Dec | ns |
| Apolipoprotein A-II | 0.049591-Dec | ns | 0.003260-Inc |
| Apolipoprotein C-I | 0.048209-Dec | ns | ns |
| Beta-2-glycoprotein 1 | 0.028184-Dec | ns | 0.002013-Inc |
| CD5 antigen-like | 0.010158-Dec | ns | 0.045895-Inc |
| Complement factor D | 0.017977-Dec | ns | ns |
| Extracellular matrix protein 1 | 0.022876-Dec | ns | ns |
| Fetuin-B | ns | 0.011128-Dec | 0.000363-Inc |
| Fibrinogen beta chain | 0.00032-Dec | ns | 0.018719-Inc |
| Gelsolin | ns | 0.016365-Dec | 0.041981-Dec |
| Insulin-like growth factor-binding protein 3 | 0.017826-Dec | ns | 0.002810-Inc |
| Insulin-like growth factor-binding protein complex acid labile subunit | ns | 0.010068-Dec | ns |
| Kallistatin | ns | ns | 0.014792-Inc |
| Lumican | ns | 0.044139-Inc | ns |
| mRNA for apolipoprotein E | 0.012596-Inc | ns | 0.043471-Dec |
| Phospholipid transfer protein | 0.016353-Dec | 0.025245-Dec | ns |
| Protein AMBP | ns | 0.045234-Dec | ns |
Notes to table: L-30–30 days prior to launch; R + 1 – the 1st day after landing; R + 7 – the 7th day after landing; Inc – increased level; Dec – decreased level; ns – no significant difference.